gemcitabine erlotinib advanced pancreatic cancer systematic review meta-analysis abstract background study aims comprehensively summarize evidences efficacy safety gemcitabine erlotinib treating advanced pancreatic cancer methodology/principal findings pubmed embase cochrane library abstracts recent major conferences systematically searched identify relevant publications studies conducted advanced pancreatic cancer patients treated gemcitabine erlotinib comparison gemcitabine reporting objective response rate disease control rate progression-free survival time-to-progression survival num year survival rate and/or adverse events included data objective response rate disease control rate num year survival rate adverse events rate combined meta-analyst software random-effects model data progression-free survival time-to-progression survival summarized descriptively sixteen studies num advanced pancreatic cancer patients treated gemcitabine erlotinib included reported median progression-free survival time-to-progression median survival num year survival rates objective response rates disease control rates num num months num num months num num num num num weighted num year survival rate objective response rate disease control rate based studies reporting robust results num num num studies relevant data incidences total severe adverse events num num frequently reported adverse events leucopenia rash diarrhea vomitting neutropenia thrombocytopenia anaemia stomatitis drug-induced liver injury fatigue fever compared gemcitabine progression-free survival survival gemcitabine erlotinib significantly longer deaths interstitial lung disease-like syndrome related treatment conclusions/significance gemcitabine erlotinib represent option treatment advanced pancreatic cancer mild clinically meaningful additive efficacy compared gemcitabine safety profile generally acceptable careful management needed specific adverse events 
